(Q37153037)

18 August 2017

1 reference

title

Dyslipidemia and glucose dysregulation in overweight and obese patients (English)

1 reference

18 August 2017

0 references

0 references

1 reference

1

Derek LeRoith

1 reference

PubMed ID

18452841

18 August 2017

language of work or name

1 reference

1 January 2007

1 reference

18 August 2017

1 reference

18 August 2017

8

1 reference

18 August 2017

3

1 reference

18 August 2017

38-52

1 reference

Obesity and diabetes in the developing world--a growing challenge

18 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

Waist circumference and cardiometabolic risk: a consensus statement from shaping America's health: Association for Weight Management and Obesity Prevention; NAASO, the Obesity Society; the American Society for Nutrition; and the American Diabetes As

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

The association of differing measures of overweight and obesity with prevalent atherosclerosis: the Dallas Heart Study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

Trends in serum lipids and lipoproteins of adults, 1960-2002.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

1 reference

7 January 2021

Disparities in use of lipid-lowering medications among people with type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

Apparent discontinuation rates in patients prescribed lipid-lowering drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

Lipid and lipoprotein dysregulation in insulin resistant states

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

Prevalence of glucose intolerance among Native Hawaiians in two rural communities. Native Hawaiian Health Research (NHHR) Project

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

Diabetes incidence and prevalence in Pima Indians: a 19-fold greater incidence than in Rochester, Minnesota

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

Economic costs of diabetes in the US in 2002.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

Hypertriglyceridemic waist: A marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men?

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

The hypertriglyceridemic waist phenotype among women

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

Clustering of metabolic abnormalities in adolescents with the hypertriglyceridemic waist phenotype.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

Postprandial triglyceride response in visceral obesity in men.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

Postprandial inflammation and endothelial dysfuction

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

Alimentary lipemia, postprandial triglyceride-rich lipoproteins, and common carotid intima-media thickness in healthy, middle-aged men.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

Increased postprandial lipemia in patients with normolipemic peripheral arterial disease

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

Postprandial hyperlipidemia: another correlate of the "hypertriglyceridemic waist" phenotype in men.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

Relationship between insulin resistance and abnormal lipid profile in obese adolescents.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

Abnormal HDL subclasses distribution in overweight children with insulin resistance or type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

Body mass index, waist circumference, waist-hip ratio, and glucose intolerance in Chinese and Europid adults in Newcastle, UK.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

Lack of association between central adiposity and lipaemia in UK Sikh men

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

Prevalence of overweight and obesity and their association with hypertension and diabetes mellitus in an Indo-Asian population

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

Defining obesity cut points in a multiethnic population

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

A rational approach to pathogenesis and treatment of type 2 diabetes mellitus, insulin resistance, inflammation, and atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

Impaired fasting glucose or impaired glucose tolerance. What best predicts future diabetes in Mauritius?

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

Abnormal glucose tolerance and increased risk for cardiovascular disease in Japanese-Americans with normal fasting glucose

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab)

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

Physical activity energy expenditure predicts progression toward the metabolic syndrome independently of aerobic fitness in middle-aged healthy Caucasians: the Medical Research Council Ely Study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

Features of the metabolic syndrome are associated with objectively measured physical activity and fitness in Danish children: the European Youth Heart Study (EYHS).

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

Association of television viewing with fasting and 2-h postchallenge plasma glucose levels in adults without diagnosed diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

Objectively measured light-intensity physical activity is independently associated with 2-h plasma glucose.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

Effect of calorie restriction with or without exercise on insulin sensitivity, beta-cell function, fat cell size, and ectopic lipid in overweight subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

Reduction in obesity and related comorbid conditions after diet-induced weight loss or exercise-induced weight loss in men. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

Comparison of the Atkins, Zone, Ornish, and LEARN diets for change in weight and related risk factors among overweight premenopausal women: the A TO Z Weight Loss Study: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

Comparison of 4 diets of varying glycemic load on weight loss and cardiovascular risk reduction in overweight and obese young adults: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

Effects of a low-glycemic load vs low-fat diet in obese young adults: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

Type 2 diabetes and cardiovascular disease: getting to the fat of the matter

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

Inflammation: the link between insulin resistance, obesity and diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

Adipose tissue and atherosclerosis: exploring the connection

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

PPAR gamma and the treatment of insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

Targeting insulin resistance and beta-cell dysfunction: the role of thiazolidinediones

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

Endocannabinoid control of food intake and energy balance

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

The endocannabinoid system and the treatment of obesity

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

Adipose tissue as an endocrine organ

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980027-5

7 January 2021

10.1016/S1098-3597(07)80027-5

Identifiers

DOI

1 reference

18 August 2017

1 reference

PubMed ID

18452841